CTLA4 and neoplasm: CTLA4-blocking antibodies and PD1- and PD-L1-blocking antibodies can release anti-tumor immune responses and lead to durable cancer regression.[30] In contrast, ICIs inhibit harmful feedback mechanisms of the immune system by blocking CTLA-4 or PD-1, leading to a durable antitumor response.